Blog Category

News

01
Jul 2020

Clinical data validates BenevolentAI's AI predicted hypothesis for baricitinib as a potential treatment for COVID-19

Research published in EMBO Molecular Medicine confirms AI predictions for anti-viral and anti-cytokine signalling effects of baricitinib in critically hospitalised COVID-19 patients
01
Jul 2020

COVID-19 and AI: An editorial review in EMBO from Michael B. Schultz, Daniel Vera, David A. Sinclair

David Sinclair and colleagues review our recent publication in the EMBO Molecular Medicine Journal in support of our AI-derived hypothesis for a potential treatment of COVID-19.
10
Apr 2020

Potential treatment for COVID-19 identified by BenevolentAI enters randomised clinical trial

BenevolentAI announced that baricitinib is entering clinical testing as a potential COVID-19 treatment. Benevolent identified the drug using its AI drug discovery platform. The trial by Eli Lilly will investigate the drug’s efficacy and safety.
26
Feb 2020

MIT Technology Review names BenevolentAI as a top 10 breakthrough tech

We’re proud to be recognised on this prestigious list for our work in AI-driven chemical design. Our compound design is based upon complex multiparametric optimisations which aim to cut the time and cost of designing a drug.